Giacomo Chiesi

Chiesi Farmaceutici SpA develops and markets pharmaceutical products. The firm specializes in research, development and production of drugs in respiratory dosage forms, such as metered-dose inhalers and sterile unit dose vials. The company was founded by Giacomo Chiesi in 1935 and is headquartered in Parma, Italy.

Sentien Biotechnologies, Inc. develops cell-based therapy for critical care. It provides the Sentinel, a device that actively treats patients during a dialysis dose by supplementing patient blood with MSC-derived secretions. The company was founded by Brian Miller and Biju Parekkadan and is headquartered in Lexington, MA.

Chiesi Ventures, Inc.(Chiesi Ventures) is an venture capital firm founded in 2014. The firm is headquartered in Boston, Massachusetts.

Part of Valline Srl, Chiesi SA (Belgium) is a Belgian pharmaceutical company specializing in the treatment of respiratory diseases, neonatology, rare diseases, and special care. Chiesi SA (Belgium is based in Machelen, BE. The company's focus on innovation and patient care has led to collaborations with other organizations, such as Affibody, and the development of new treatments for rare diseases. Chiesi SA (Belgium is committed to sustainability and participates in events such as Climbing for Life. The company was founded in 2010 by Giacomo Chiesi, and the CEO is Alberto Chiesi.

Chiesi Pharma AB is a private company that engages in research and development, manufacturing, and selling of medicines. Chiesi Pharma AB is based in Stockholm, Sweden. It was founded in 1935 by Giacomo Chiesi, and the CEO is Olav Henrik Fromm.

Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA.